Merck stock trades near record territory as oncology and vaccines drive revenue growth

Merck stock has been supported by solid recent financial performance, as Merck & Co., Inc. (ISIN US58933Y1055) reported strong growth in its core oncology and vaccines franchises in the latest quarterly results. In its most recently available quarter, the US pharmaceutical group reported total revenue of around $15.8 billion, reflecting robust demand in key therapeutic areas and a high contribution from cancer drug sales. Investors have focused on the company’s ability to grow oncology and vaccine revenue while managing patent expirations and investing in its pipeline.

Revenue up over ten percent

According to Merck’s latest quarterly earnings release, the company generated approximately $15.8 billion in total revenue in the reported quarter, an increase of around 10% compared with the same period a year earlier. This double-digit expansion was driven largely by oncology therapies and vaccines, which together represented a substantial share of group sales in that period. The revenue growth came despite headwinds from loss of exclusivity in certain mature products, underlining the importance of newer franchises for the group.

Within that total, oncology remains the key growth engine. Merck’s blockbuster cancer therapy Keytruda contributed roughly $6.9 billion in revenue in the quarter, up from about $5.8 billion in the prior-year quarter. This implies year-on-year growth of around 19%, illustrating how continued uptake in indications such as lung cancer and melanoma is offsetting pricing pressure and competitive dynamics. For investors, the magnitude of that increase matters: nearly one third of Merck’s quarterly revenue now stems from Keytruda alone, highlighting concentration but also the strength of the oncology portfolio.

Keytruda and vaccines add scale

The vaccine franchise adds another pillar to Merck’s growth story. In the same reporting period, vaccine sales including the human papillomavirus (HPV) vaccine Gardasil and Gardasil 9 reached roughly $2.5 billion, compared with about $2.0 billion a year earlier. This represents an increase of 25%, driven by higher demand in multiple geographies and expanded immunization programs. The acceleration in vaccine revenue complements oncology and helps diversify the group’s product mix, which investors often view as important for long-term resilience.

On the profitability side, Merck reported reported earnings per share (EPS) from continuing operations of about $2.07 in the quarter, compared with roughly $1.40 in the same quarter of the previous year. This almost 48% year-on-year increase reflects operating leverage as higher revenue in oncology and vaccines more than offset increased research and development spending. The company’s operating margin also improved versus the prior-year period, supported by favorable product mix and disciplined cost control. For shareholders, the combination of double-digit top-line growth and strong EPS expansion reinforces the perception that Merck is executing well on its strategy.

Pipeline investment and guidance

Beyond current-quarter figures, Merck has emphasized ongoing investment in its research pipeline, including oncology, immunology, and infectious disease candidates. In the most recent full fiscal year, Merck’s research and development expenses amounted to approximately $13.8 billion, up from about $12.2 billion in the previous year. The roughly 13% increase underscores the company’s focus on sustaining innovation that can replace revenue from products facing patent expirations later this decade. These investments are particularly relevant in the context of anticipated Keytruda patent cliffs in key markets, where Merck aims to offset potential future declines with new therapies.

At the group level, Merck issued full-year guidance in its latest annual outlook, projecting total revenue in a range of approximately $60 billion to $61.5 billion, compared with prior-year revenue in the neighborhood of $60.1 billion. This implies modest single-digit growth for the full year, which contrasts with the stronger quarterly performance but reflects cautious assumptions around currency, competition, and the timing of new launches. Investors often compare Merck’s guidance to consensus expectations; the company’s forecast suggests management is balancing optimism about oncology and vaccines with prudence about macroeconomic and regulatory conditions.

Keytruda revenue above $6.9 billion

Merck’s reliance on Keytruda is central to many equity research discussions. The approximately $6.9 billion quarterly revenue from the drug represents a substantial portion of the company’s oncology business and continues to grow in absolute terms. Year-on-year expansion of roughly $1.1 billion demonstrates ongoing uptake across different indications and geographies. Observers often compare Keytruda’s trajectory with rival immuno-oncology drugs from other large pharmaceutical groups, noting that Merck’s product maintains a significant share in important cancer treatment segments.

At the same time, Merck is broadening its oncology portfolio through combination therapies and new indications. Clinical studies pairing Keytruda with other agents aim to improve outcomes in tumours where monotherapy effectiveness is limited. These efforts could both extend the life of the franchise and support future revenue streams, though they also require substantial R&D spending. The balance between current profitability and future-oriented investment is a recurring theme in the company’s communications with the market.

Gardasil vaccine growth supports diversification

The Gardasil and Gardasil 9 vaccines play a crucial role in Merck’s diversification beyond oncology. With quarterly revenue of approximately $2.5 billion and year-on-year growth of 25%, these products illustrate how preventative medicine can contribute meaningfully to a large pharmaceutical company’s financial results. Higher vaccination rates in multiple regions and expanded age eligibility have reinforced the upward trend in sales. Gardasil’s global reach also mitigates regional revenue concentration, offering some buffer against country-specific pricing or regulatory developments.

Merck’s broader vaccine portfolio includes products targeting diseases such as measles, mumps, and varicella, among others. While smaller in absolute terms than Gardasil, these vaccines add incremental revenue and maintain Merck’s positioning in immunization programs worldwide. The strategic importance lies in the combination of high-profile oncology assets and relatively steady vaccine income, which together can smooth revenue volatility across economic cycles and competitive shifts.

Product focus on Keytruda

Keytruda has become one of the most commercially important cancer therapies globally, and for Merck & Co. it is the flagship product in oncology. The drug is approved for a wide range of indications, including non-small cell lung cancer, melanoma, head and neck cancer, and certain types of colorectal and gastric cancers, among others. Its mechanism as a programmed cell death protein 1 (PD-1) inhibitor has made it a cornerstone of immuno-oncology treatment regimens in many markets.

From a financial perspective, Keytruda’s roughly $6.9 billion revenue in the latest quarter and nearly 19% year-on-year growth underline the drug’s central role in Merck’s income statement. The company continues to invest in additional trials to expand the label, which could sustain growth in the medium term. However, patent expirations later in the decade represent a key strategic challenge. Merck’s response includes developing next-generation oncology candidates and exploring combinations that may preserve the value of its immuno-oncology platform even as individual patents expire.

Merck stock and valuation context

Merck stock is listed on the New York Stock Exchange, where it is part of major US equity benchmarks used by global investors. Recent trading data from major financial portals show Merck shares changing hands near record territory, with a price level close to the upper end of their 52-week range. The company’s market capitalization has been reported at well over $250 billion as of recent data, reflecting the scale of its operations and the perceived value of its pipeline and cash flows. For many asset managers, Merck is a core holding within the large-cap pharmaceutical segment.

Valuation discussions often compare Merck’s price-to-earnings and enterprise value to earnings multiples with those of other big-pharma firms, taking into account the high contribution of Keytruda and Gardasil. While headline revenue and EPS growth rates have been strong, the market also prices in future risks such as patent expiry and competitive pressure in oncology and vaccines. As a result, Merck’s equity story combines near-term momentum with longer-term strategic questions about how the company will evolve beyond its current blockbusters.